ORAL ANTI-DIABETES DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The Oral Anti-diabetes Drugs Market is segmented by Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides), and Geography.

Market Snapshot

 Oral Anti-diabetes Drugs Market Overview
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >4 %
 Oral Anti-diabetes Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Oral Anti-diabetes Drugs Market is estimated to be more than USD 39.2 billion in 2019, and it is growing because of the rise in the Type 2 diabetes population. The significant growth in the market can be attributed to factors such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. In 2019, it was estimated that out of 511 million people suffering from diabetes, 31.3% were undiagnosed. In 2019, diabetes was the cause of 4.2 million deaths per year, making it the eighth leading cause of death, worldwide. The diabetic condition, on the whole, doubles the risk of death. Currently, about 10% of all diabetes cases are Type-1 and the remaining are of Type-2. Thus, the rise in the prevalence of type-2 diabetes worldwide is likely to create a vast demand for diabetes drugs. 

Scope of the Report

A holistic study of the market has been carried out by incorporating various factors, extending from country-specific demographic conditions and business cycles to market-specific macroeconomic influences that are needed to analyze future trends. The research uncovers many paradigm shifts in the market studied, in terms of brand-level market dynamics. The oral anti-diabetes drug market is segmented by drugs (biguanides, alpha-glucosidase inhibitors, dopamine-D2 receptor agonists, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, sulfonylureas, and meglitinides) and geography.

By Drug (Value and Volume 2012-2025)
Biguanides
Metformins
Alpha-glucosidase inhibitors
Alpha-glucosidase Inhibitors
Dopamine -D2 Receptor Agonist
Bromocriptin (Cycloset)
Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Geography
North America
United States (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Canada (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of North America (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Europe
France (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Germany (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Italy (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Spain (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
United Kingdom (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Russia (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of Europe (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Latin America
Mexico (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Brazil (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of Latin America (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Asia-Pacific
Japan (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
South Korea (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
China (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
India (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Australia (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Vietnam (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Malaysia (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Indonesia (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Philippines (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Thailand (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of Asia-Pacific (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Middle-East and Africa
Saudi Arabia (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Iran (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Egypt (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Oman (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
South Africa (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of Middle-East and Africa (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

Report scope can be customized per your requirements. Click here.

Key Market Trends

DPP-4 Inhibitors Segment Held the Largest Market Share in 2019

The Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors segment of the oral anti-diabetes drug market was valued at more than USD 7 million in 2019, and it is expected to record a CAGR lesser than 4% during the forecast period (2019-2025). DPP-4 inhibitor drugs are gaining momentum in the market because the products do not seem to have any effect on primary adverse cardiovascular outcomes and risk for heart failure. Besides, they can be used both as a combination therapy with insulin, sulphonylureas, and dipeptidyl peptidase-4 drugs and as a monotherapy, thus, making it a widely used class of drugs. During the forecast period, the DPP-4 inhibitors segment is expected to witness constant growth rate, due to the introduction of new drugs that have improved efficacy, like glucagon-like peptide (GLP-1) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. The segment is still expected to maintain the largest market share among all oral anti-diabetes drugs market segments.

 Oral Anti-diabetes Drugs Market Key Trends

Asia-Pacific leading the Oral Anti-diabetes Drugs Market

Currently, North America holds the major share in the oral anti-diabetes drugs market. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period. This is due to the high prevalence of diabetes in this region, which caused consequent adverse health and economic consequences. The rates of newly diagnosed cases of Type 1 and Type 2 diabetes are increasing among the youth in the Asia-Pacific region. In 2019, China and India, around 123.6 million people and 76.79 million people, respectively, are living with diagnosed diabetes. Moreover, an increase in the launch of new drugs with improved efficacy and high reimbursement for medicines is expected to have a positive impact on the oral anti-diabetes drug market. The increasing incidence and prevalence of diabetes and the increasing healthcare expenditure in the Asia-Pacific countries are an indication of the increasing usage of oral anti-diabetes drugs.

 Oral Anti-diabetes Drugs Market Growth by Region

Competitive Landscape

The oral anti-diabetes drug market is consolidated, with few major manufacturers having a global market presence, while the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs. For instance, Oramed is performing research on the new molecule ORMD-0801, which is the first oral insulin capsule that has the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug (Value and Volume 2012-2025)

      1. 5.1.1 Biguanides

        1. 5.1.1.1 Metformins

      2. 5.1.2 Alpha-glucosidase inhibitors

        1. 5.1.2.1 Alpha-glucosidase Inhibitors

      3. 5.1.3 Dopamine -D2 Receptor Agonist

        1. 5.1.3.1 Bromocriptin (Cycloset)

      4. 5.1.4 Sodium-glucose Cotransport -2 (SGLT-2) inhibitor

        1. 5.1.4.1 Invokana (Canagliflozin)

        2. 5.1.4.2 Jardiance (Empagliflozin)

        3. 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 5.1.4.4 Suglat (Ipragliflozin)

      5. 5.1.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors

        1. 5.1.5.1 Januvia (Sitagliptin)

        2. 5.1.5.2 Onglyza (Saxagliptin)

        3. 5.1.5.3 Tradjenta (Linagliptin)

        4. 5.1.5.4 Vipidia/Nesina (Alogliptin)

        5. 5.1.5.5 Galvus (Vildagliptin)

      6. 5.1.6 Sulfonylureas

        1. 5.1.6.1 Sulfonylureas

      7. 5.1.7 Meglitinides

        1. 5.1.7.1 Meglitinides

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume 2012-2025)

          1. 5.2.1.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        2. 5.2.1.2 Canada (Value and Volume 2012-2025)

          1. 5.2.1.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        3. 5.2.1.3 Rest of North America (Value and Volume 2012-2025)

          1. 5.2.1.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume 2012-2025)

          1. 5.2.2.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        2. 5.2.2.2 Germany (Value and Volume 2012-2025)

          1. 5.2.2.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        3. 5.2.2.3 Italy (Value and Volume 2012-2025)

          1. 5.2.2.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        4. 5.2.2.4 Spain (Value and Volume 2012-2025)

          1. 5.2.2.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        5. 5.2.2.5 United Kingdom (Value and Volume 2012-2025)

          1. 5.2.2.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        6. 5.2.2.6 Russia (Value and Volume 2012-2025)

          1. 5.2.2.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        7. 5.2.2.7 Rest of Europe (Value and Volume 2012-2025)

          1. 5.2.2.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume 2012-2025)

          1. 5.2.3.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        2. 5.2.3.2 Brazil (Value and Volume 2012-2025)

          1. 5.2.3.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        3. 5.2.3.3 Rest of Latin America (Value and Volume 2012-2025)

          1. 5.2.3.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume 2012-2025)

          1. 5.2.4.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        2. 5.2.4.2 South Korea (Value and Volume 2012-2025)

          1. 5.2.4.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        3. 5.2.4.3 China (Value and Volume 2012-2025)

          1. 5.2.4.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        4. 5.2.4.4 India (Value and Volume 2012-2025)

          1. 5.2.4.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        5. 5.2.4.5 Australia (Value and Volume 2012-2025)

          1. 5.2.4.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        6. 5.2.4.6 Vietnam (Value and Volume 2012-2025)

          1. 5.2.4.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        7. 5.2.4.7 Malaysia (Value and Volume 2012-2025)

          1. 5.2.4.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        8. 5.2.4.8 Indonesia (Value and Volume 2012-2025)

          1. 5.2.4.8.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        9. 5.2.4.9 Philippines (Value and Volume 2012-2025)

          1. 5.2.4.9.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        10. 5.2.4.10 Thailand (Value and Volume 2012-2025)

          1. 5.2.4.10.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2025)

          1. 5.2.4.11.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume 2012-2025)

          1. 5.2.5.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        2. 5.2.5.2 Iran (Value and Volume 2012-2025)

          1. 5.2.5.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        3. 5.2.5.3 Egypt (Value and Volume 2012-2025)

          1. 5.2.5.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        4. 5.2.5.4 Oman (Value and Volume 2012-2025)

          1. 5.2.5.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        5. 5.2.5.5 South Africa (Value and Volume 2012-2025)

          1. 5.2.5.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume 2012-2025)

          1. 5.2.5.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

  6. 6. MARKET INDICATORS

    1. 6.1 Type 1 Diabetes Population (2012-2025)

    2. 6.2 Type 2 Diabetes Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Sanofi S.A.

      2. 7.1.2 Eli Lilly and Company

      3. 7.1.3 AstraZeneca plc

      4. 7.1.4 Astellas Pharma Inc.

      5. 7.1.5 Johnson & Johnson (Janssen Pharmaceuticals)

      6. 7.1.6 Boehringer Ingelheim

      7. 7.1.7 Merck And Co.

      8. 7.1.8 Takeda

      9. 7.1.9 Bristol Myers Squibb

      10. 7.1.10 Novartis

      11. 7.1.11 Pfizer

    2. 7.2 Company Share Analysis

      1. 7.2.1 Sanofi S.A.

      2. 7.2.2 Eli Lilly and Company

      3. 7.2.3 AstraZeneca plc

      4. 7.2.4 Astellas Pharma Inc.

      5. 7.2.5 Johnson & Johnson (Janssen Pharmaceuticals)

      6. 7.2.6 Merck and Co.

      7. 7.2.7 Other Companies Analysis

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The oral anti-diabetes drugs Market market is studied from 2016 - 2027.

The oral anti-diabetes drugs Market is growing at a CAGR of >4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Eli Lilly and Company, Johnson & Johnson (Janssen Pharmaceuticals), Astellas Pharma Inc., AstraZeneca plc, Sanofi S.A. are the major companies operating in oral anti-diabetes drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!